Current ebola vaccines.

Expert Opinion on Biological Therapy
T HoenenHeinz Feldmann

Abstract

Ebolaviruses cause severe viral hemorrhagic fever in humans and non-human primates (NHPs), with case fatality rates of up to 90%. Currently, neither a specific treatment nor a vaccine licensed for use in humans is available. However, a number of vaccine candidates have been developed in the last decade that are highly protective in NHPs, the gold standard animal model for ebola hemorrhagic fever. This review analyzes a number of scenarios for the use of ebolavirus vaccines, discusses the requirements for ebolavirus vaccines in these scenarios and describes current ebolavirus vaccines. Among these vaccines are recombinant adenoviruses, recombinant vesicular stomatitis viruses (VSVs), recombinant human parainfluenza viruses and virus-like particles. Interestingly, one of these vaccine platforms, based on recombinant VSVs, has also demonstrated post-exposure protection in NHPs. The most pressing remaining challenge is now to move these vaccine candidates forward into human trials and toward licensure. In order to achieve this, it will be necessary to establish the mechanisms and correlates of protection for these vaccines, and to continue to demonstrate their safety, particularly in potentially immunocompromised populations. Howev...Continue Reading

References

Jul 1, 1978·The Journal of Pathology·A BaskervilleD I Simpson
Jan 1, 1978·Transactions of the Royal Society of Tropical Medicine and Hygiene·E T BowenR T Raymond
Feb 13, 1999·The Journal of Infectious Diseases·B M ConnollyP B Jahrling
Feb 13, 1999·The Journal of Infectious Diseases·M BrayJ Huggins
May 9, 2002·Emerging Infectious Diseases·Thomas W GeisbertPeter B Jahrling
Apr 11, 2003·Virus Research·Jenny L Mellquist-RiemenschneiderConnie S Schmaljohn
Dec 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Kelly L WarfieldSina Bavari
Jun 24, 2005·PLoS Medicine·Thomas W GeisbertHeinz Feldmann
Dec 2, 2005·Nature·Eric M LeroyRobert Swanepoel
Dec 17, 2005·Virology·Gary P KobingerJames M Wilson
Jul 20, 2006·PLoS Pathogens·Hideki EbiharaYoshihiro Kawaoka
Aug 9, 2006·The Journal of General Virology·Soumitra RoyJames M Wilson
Sep 16, 2006·Journal of Virology·Kathleen M Daddario-DiCaprioSteven M Jones
Sep 22, 2006·Clinical and Vaccine Immunology : CVI·Julie E MartinBarney S Graham
Dec 13, 2006·Science·Magdalena BermejoPeter D Walsh
Jan 24, 2007·PLoS Pathogens·Heinz FeldmannThomas W Geisbert
Apr 13, 2007·Journal of Virology·Alexander BukreyevAnthony Sanchez
Aug 19, 2007·Trends in Microbiology·Allison GrosethJames E Strong
Dec 6, 2007·The Journal of Infectious Diseases·Lisa E HensleyThomas W Geisbert
Dec 6, 2007·The Journal of Infectious Diseases·Steven M JonesHeinz Feldmann
Dec 6, 2007·The Journal of Infectious Diseases·Kelly L WarfieldSina Bavari
Dec 6, 2007·The Journal of Infectious Diseases·Kelly L WarfieldSina Bavari
Jan 24, 2008·Proceedings of the National Academy of Sciences of the United States of America·Peter HalfmannYoshihiro Kawaoka
Nov 22, 2008·PLoS Pathogens·Jonathan S TownerStuart T Nichol

❮ Previous
Next ❯

Citations

Oct 17, 2014·The Journal of Venomous Animals and Toxins Including Tropical Diseases·Jean-Philippe Chippaux
Nov 18, 2015·Proceedings of the National Academy of Sciences of the United States of America·Audrey Stéphanie RichardHyeryun Choe
Nov 13, 2015·Reviews in Medical Virology·Gurpreet SinghJagdeep Kaur
Nov 26, 2015·Virus Research·Elijah Ige Ohimain
Dec 3, 2014·Advanced Drug Delivery Reviews·Nishant K JainC Russell Middaugh
Jun 10, 2015·Virus Research·Carles Martínez-Romero, Adolfo García-Sastre
Jul 15, 2015·Medicinal Research Reviews·Zlatko Janeba
Mar 1, 2014·Expert Review of Vaccines·Andrea Marzi, Heinz Feldmann
Sep 28, 2014·Journal of Autoimmunity·Aftab A Ansari
Dec 4, 2014·Mayo Clinic Proceedings·Pritish K Tosh, Priya Sampathkumar
Dec 17, 2014·Microbes and Infection·Haoyang LiShibo Jiang
Feb 5, 2015·Clinical and Experimental Vaccine Research·Woo Young ChoiWon-Ja Lee
Apr 27, 2016·American Journal of Infection Control·Huijun XiLingjuan Zhang
May 30, 2015·PLoS Neglected Tropical Diseases·Chad WellsAlison P Galvani
Aug 30, 2014·Expert Review of Anti-infective Therapy·Thomas Hoenen, Heinz Feldmann
Sep 24, 2016·Revista da Associação Médica Brasileira·Daniela Alexandra de Meneses Rocha Aguiar PachecoCarmen Maria Lisboa da Silva
Mar 28, 2017·Frontiers in Immunology·Sergio Rosales-MendozaCarlos Angulo
Oct 8, 2019·Human Vaccines & Immunotherapeutics·John J Suschak, Connie S Schmaljohn
Jul 31, 2021·Current Opinion in Pharmacology·Ashish Ranjan SharmaSang-Soo Lee
Jan 9, 2018·ACS Nano·Raffaele RiccòPaolo Falcaro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.